FundedIQ
Biotechnology

MaaT Pharma: Funding, Investors & Team (Sep 2026)

MaaT Pharma, a clinical stage company, has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating a range of cancers and Graft-versus-Host-Disease, a serious complication of allogeneic stem cell transplantation, MaaT Pharma has already achieved proof of concept in acute myeloid leukemia patients. Supporting the further expansion of our pipeline into improving outcomes of immunotherapy in solid tumors, we have built a powerful discovery and analysis platform, GutPrint®, to evaluate drug candidates, determine novel disease targets and identify biomarkers for microbiome-related conditions.

maatpharma.com LinkedIn Lyon, France 11-50 employees
Total raised
$66.0M
Rounds
3
Latest
Undisclosed round
Jul 2025

MaaT Pharma has raised $66.0M across 3 funding rounds on record, the most recent an undisclosed round of $44.1M announced in Jul 2025.

That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.

MaaT Pharma Company Profile and Key Stats

Total funding raised
$66.0M
across 3 rounds on record
Funding rounds on record
3
Latest funding round
Undisclosed round
$44.1M in Jul 2025
Employees
11-50
reported band
Headquarters
Lyon, France

Latest funding round on record: Jul 2025.

MaaT Pharma Funding Rounds

Date
Round
Amount
Undisclosed round
$44.1M
Undisclosed round
$19.7M
Grant
$2.2M

MaaT Pharma raised $2.2M in a Grant announced in Jul 2021.

2.8 years later, an undisclosed round of $19.7M was announced in May 2024.

1.2 years later, an undisclosed round of $44.1M was announced in Jul 2025.

MaaT Pharma Founders and Leadership Team

Name
Role
Contact
Herve Affagard
Founder

No contact details are on record for this team yet.

MaaT Pharma Funding Compared to Other Biotechnology Startups

Segment
Companies
Median round
4,179
$8.0M
1,705
$6.7M

MaaT Pharma's latest round of $44.1M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.

Funded Startups Like MaaT Pharma in Biotechnology and Lyon

Companies Similar to MaaT Pharma

Brenus Pharma is a platform that uses allogeneic techniques to create immune therapy with the goal of…

Series A $12.6M

TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid…

Series D $34.0M

NicOx is a biopharmaceutical company that focuses on creating and selling nitric oxide-donating drugs for…

Undisclosed round $6.9M

Advicenne is a specialty pharmaceutical company dedicated to improving the lives of patients who suffer from…

Undisclosed round $1.7M

One Biosciences was founded in Paris, Ile-de-France, France by Magali Richard, David Schilansky, and Céline…

Undisclosed round

Inventiva Pharma is a biopharmaceutical company in the clinical stage that focuses on creating oral small…

Undisclosed round $120M

NETRIS Pharma develops therapeutic molecules for treating cancer by targeting dependence receptors for the…

Undisclosed round $8.4M

AbIONYX Pharma is a biotechnology company that is focused on providing innovative therapies for indications…

Undisclosed round $11.6M

Founded in 2003, Nanobiotix is at the forefront of nanomedicine and is committed to revolutionizing patient…

Undisclosed round $116M

Theraclion specializes in high-tech medical equipment using high-intensity focused ultrasound (HIFU). They…

Undisclosed round $7.0M

Abivax, a clinical stage biotechnology company, is mobilizing the body’s natural immune machinery to treat…

Undisclosed round $45.0M

AB Science was established in 2001 by a group of individuals in the medical and business fields who are…

Undisclosed round $3.7M

MaaT Pharma Funding FAQs

What does MaaT Pharma do?

MaaT Pharma, a clinical stage company, has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating a range of cancers and Graft-versus-Host-Disease, a serious complication of allogeneic stem cell transplantation, MaaT Pharma has already achieved proof of concept in acute myeloid leukemia patients. Supporting the further expansion of our pipeline into improving outcomes of immunotherapy in solid tumors, we have built a powerful discovery and analysis platform, GutPrint®, to evaluate drug candidates, determine novel disease targets and identify biomarkers for microbiome-related conditions.

How much funding has MaaT Pharma raised?

MaaT Pharma has raised $66.0M across 3 rounds on record. The most recent is an undisclosed round of $44.1M announced in Jul 2025.

When did MaaT Pharma last raise funding?

MaaT Pharma's most recent funding round on record is an undisclosed round of $44.1M, announced in Jul 2025.

Who founded MaaT Pharma?

FundedIQ lists Herve Affagard (Founder) at MaaT Pharma.

Where is MaaT Pharma headquartered?

MaaT Pharma is based in Lyon, Rhone-Alpes, France.

How many employees does MaaT Pharma have?

MaaT Pharma is in the 11-50 employee band.

How does MaaT Pharma's funding compare to other Biotechnology startups?

MaaT Pharma's latest round of $44.1M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.

About FundedIQ's MaaT Pharma Funding Data

FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.

Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for MaaT Pharma is left off this page rather than filled in.

14-day free trial · Cancel anytime

Know who just raised. Then know who to reach.

Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.

Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.